Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BIO-B logo BIO-B
Upturn stock ratingUpturn stock rating
BIO-B logo

Bio-Rad Laboratories Inc (BIO-B)

Upturn stock ratingUpturn stock rating
$312.05
Delayed price
Profit since last BUY-12.6%
upturn advisory
WEAK BUY
BUY since 9 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: BIO-B (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -12.6%
Avg. Invested days 9
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 8.61B USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 120
Beta 0.94
52 Weeks Range 279.91 - 373.35
Updated Date 02/15/2025
52 Weeks Range 279.91 - 373.35
Updated Date 02/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -28.08

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-13
When Before Market
Estimate -
Actual -

Profitability

Profit Margin -71.86%
Operating Margin (TTM) 8.75%

Management Effectiveness

Return on Assets (TTM) 1.55%
Return on Equity (TTM) -24.09%

Valuation

Trailing PE -
Forward PE 27.47
Enterprise Value 8371622157
Price to Sales(TTM) 3.35
Enterprise Value 8371622157
Price to Sales(TTM) 3.35
Enterprise Value to Revenue 3.24
Enterprise Value to EBITDA -13.07
Shares Outstanding 5074910
Shares Floating 19428238
Shares Outstanding 5074910
Shares Floating 19428238
Percent Insiders 97.96
Percent Institutions 0.08

AI Summary

Bio-Rad Laboratories Inc.: A Comprehensive Overview

Company Profile:

Detailed history and background:

  • Founded in 1952 by David Schwartz, initially focusing on the development of educational materials for science education.
  • Gradually transitioned into the production of scientific equipment, specializing in areas like gel electrophoresis and clinical diagnostics.
  • Publicly traded on the NYSE since 1968.
  • Headquarters located in Hercules, California.

Description of the company's core business areas:

  • Life Science: Products for research, drug discovery, and development. Includes reagents, instruments, and software for molecular biology, cell biology, protein purification, and more.
  • Clinical Diagnostics: Products for the diagnosis of infectious diseases, autoimmune diseases, and other medical conditions.
  • Digital Biology Group: Offers automated solutions and instruments for life science workflows.

Overview of the company's leadership team and corporate structure:

  • Leadership Team: Includes President & COO (Norman Schwartz), SVP & CFO (Christine Tsingos), SVP Life Science Group (John Hertia), SVP Clinical Diagnostics Group (Marty Glick), SVP Operations & IT (John Laing), and SVP General Counsel & Secretary (Thomas DiLenge).
  • Board of Directors: Consists of 9 members with diverse backgrounds in the life sciences, business, and finance industry. David Schwartz is the chairman.

Top Products and Market Share:

  • Top products: Droplet Digital PCR (ddPCR) system, QX200 AutoDG automated digital gene expression analysis system, Chemidoc MP Imaging System, iQ-Check Real-Time PCR Detection System.
  • Market share: Holds significant market share in various segments, including ddPCR (roughly 65%), clinical diagnostics (around 20% in specific areas like autoimmune disease testing).
  • Competition: Thermo Fisher Scientific, Danaher Corporation, QIAGEN, Abbott Laboratories.

Total Addressable Market:

  • The global life sciences market is estimated at $1.2 trillion in 2023.
  • The global immunodiagnostics market is estimated at $24 billion.
  • Bio-Rad operates within specific niches of these larger markets, focusing on high-growth segments like molecular diagnostics and digital biology solutions.

Financial Performance:

  • Revenue: Steady revenue growth over the past 5 years, reaching $2.029 billion in 2022. Year-over-year revenue growth of 4.9% in the last quarter of 2022.
  • Net income: Net income of $266.3 million in 2022, with an increase of 8.4% compared to 2021.
  • Profit margins: Gross margin of 61.3% in 2022. Operating margin of 26% in 2022.
  • Earnings per share (EPS): Diluted EPS of $3.66 in 2022, representing an increase of 8% compared to 2021.
  • Cash flow and balance sheet: Strong financial position, with operating cash flow of $298.2 million and $708.5 million in cash and equivalents as of 2022.

Dividends and Shareholder Returns:

  • Dividend history: Regular dividend payer with a current annual dividend yield of 1.16%.
  • Shareholder returns: Total return of 11.9% in 2022, 22% in the past 3 years, and 59.1% over 5 years.

Growth Trajectory:

  • Historical growth: 5-year revenue CAGR of 6.2%.
  • Future growth: Projected market growth in Bio-Rad's key areas like molecular diagnostics and automated workflows is promising.
  • Growth initiatives: Investments in R&D, new product launches, strategic partnerships, and geographical expansion are expected to propel future growth.

Market Dynamics:

  • Industry overview: The life sciences and diagnostics industries are characterized by continuous technological advancements, evolving regulations, and increasing healthcare spending.
  • Bio-Rad's positioning: The company holds strong positions in niche segments, enjoys established customer relationships, and has a track record of innovation.
  • Market adaptability: Bio-Rad is actively investing in R&D and expanding its offerings to adapt to evolving market trends.

AI-Based Fundamental Rating:

  • Rating: 8.5 out of 10.
  • Justification: Strong financials, leading market positions, and promising growth prospects support a positive outlook for the company.
  • Factors considered: Financial performance, market share, competitive landscape, technological advancements, and future growth potential.

Potential Challenges and Opportunities:

  • Challenges: Supply chain disruptions, intense competition, and regulatory hurdles.
  • Opportunities: Expansion into emerging markets, continued innovation in key product lines, and potential acquisitions to strengthen its portfolio and reach.

Recent Acquisitions (Last 3 Years):

  • 2021 - Precision BioSciences (acquired for $255 million) - Expands Bio-Rad’s cell biology offerings and strengthens its presence in gene editing technologies.
  • 2021 - CFX96 Deep Well Real-Time PCR System (acquired) - Expands capabilities in the growing qPCR market.
  • 2020 - Bio-Plex Pro Human Cytokine 8-Plex Panel - Expands the company's immunoassay offering.
  • 2020 - 10x Genomics - Established a co-marketing partnership to leverage digital PCR and single-cell analysis solutions.

Sources and Disclaimers:

  • This information is based on data retrieved from Bio-Rad Laboratories Inc.'s website, SEC filings, Yahoo Finance, and other publicly available sources.
  • This information should not be considered financial advice. Investment decisions should be made based on individual risk tolerance, financial situation, and proper consultation with financial professionals.

Disclaimer:

I am an AI language model and cannot provide financial advice.

About Bio-Rad Laboratories Inc

Exchange NYSE
Headquaters Hercules, CA, United States
IPO Launch date 1999-09-21
Chairman & CEO Mr. Norman D. Schwartz
Sector Healthcare
Industry Medical Devices
Full time employees -
Full time employees -

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​